Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other financing activities (2016 - 2022)

Historic Other financing activities for Cumberland Pharmaceuticals (CPIX) over the last 14 years, with Q1 2022 value amounting to -$370464.0.

  • Cumberland Pharmaceuticals' Other financing activities fell 23229.91% to -$370464.0 in Q1 2022 from the same period last year, while for Mar 2022 it was -$650484.0, marking a year-over-year decrease of 40985.96%. This contributed to the annual value of $135405.0 for FY2020, which is 8645.95% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Other financing activities of -$370464.0 as of Q1 2022, which was down 23229.91% from -$632646.0 recorded in Q4 2021.
  • Cumberland Pharmaceuticals' 5-year Other financing activities high stood at $1.0 million for Q3 2019, and its period low was -$670985.0 during Q4 2020.
  • For the 5-year period, Cumberland Pharmaceuticals' Other financing activities averaged around $169073.1, with its median value being $248108.0 (2018).
  • In the last 5 years, Cumberland Pharmaceuticals' Other financing activities tumbled by 31072.13% in 2020 and then soared by 18139.46% in 2021.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Other financing activities stood at $135202.0 in 2018, then soared by 135.52% to $318423.0 in 2019, then crashed by 310.72% to -$670985.0 in 2020, then grew by 5.71% to -$632646.0 in 2021, then skyrocketed by 41.44% to -$370464.0 in 2022.
  • Its Other financing activities stands at -$370464.0 for Q1 2022, versus -$632646.0 for Q4 2021 and $452536.0 for Q3 2021.